VJHemOnc Podcast

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting. In this podcast, Andrew Wei, MBBS, PhD, Peter...

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting. In this podcast, Naval Daver, MD, The Universi...

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight into the sessions that took place at this year’s meeting. In this podcast, Ravi Majeti, MD, PhD, Stanfor...

Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of MRD testing has increased in recent years. MRD can indicate the depth of response to treatment as well as patient outcomes, leading to suggestions of using MRD status to guide the treatment of patients with myeloma.  In this podcast, you will hear from Meral Beksac, MD, Ankara...

The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent years, the introduction of immunotherapies including CAR-T cells and bispecific antibodies has provided hope for several patients. While both CAR-T cells and bispecific antibodies have their benefits, there are several factors to consider when evaluating their c...

Myelodysplastic syndromes (MDS) represent a heterogeneic group of disorders which remain a challenge to diagnose and treat. In recent years, there has been an increased interest in understanding various pre-MDS states, including idiopathic cytopenia of unknown significance (ICUS), clonal hematopoiesis of indeterminate potential (CHIP), and clonal cytopenia of unknown significance (CCUS). The ident...

Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP). Several mutations, including ASXL1, EZH2, and TP53, are involved in progression to MPN-AP/BP, and there are a number of challenges with treating patients who progress to this stage.  In this podcast, Anand Patel, MD, University of Chicago, Chicago,...

Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory (R/R) disease. While both of these therapies offer benefits to patients, there are challenges to address regarding the optimal sequencing of these agents. In this podcast, experts Salomon Manier, MD, PhD, Lille University Hospital, Lille, Fran...

CAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies, providing hope to several individuals with a high unmet medical need. Although CAR-T cells have demonstrated promising efficacy in patients, there are several challenges that need to be overcome before these are optimally used in clinical practice.  In this podcast, you will he...

Myeloproliferative neoplasms (MPNs) represent a challenging group of diseases to treat, and patients with MPNs suffer from several symptoms which negatively impact their quality of life (QoL). Novel agents, including JAK inhibitors, have demonstrated an ability to reduce symptom burden in patients with MPNs, and there is ongoing research aimed at improving symptom management and QoL in these patie...

Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage. The diagnosis and treatment of this disease remain a major challenge, with several novel agents being explored in clinical trials. Furthermore, clinicians and researchers are drawing attention to the important role of the multidisciplinary team (MDT) in the treatment and...

Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of life. Factor replacement therapy has been the standard of care in hemophilia, although there are limitations to this approach. More recently, the approval of novel gene therapies has presented a promising option for patients with both hemophilia A and B. In this podca...

Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment landscape of chronic lymphocytic leukemia (CLL), with both covalent and non-covalent agents being explored. There are several questions surrounding the sequencing and selection of these agents, and clinical trials exploring their efficacy. At the 2023 EHA meeting, leading experts from around the globe came together to discuss...

In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients with relapsed/refractory (R/R) disease. Several clinical trials are evaluating the efficacy of CAR-T cells and are further exploring the possibility of bringing these agents into earlier lines of therapy. At the 2023 EHA meeting, leading experts from around the globe c...

The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and CAR-T cells demonstrating promising results. At the 2023 EHA meeting, leading experts from around the globe came together to discuss the latest updates in all areas of hematological oncology.  In this podcast, you will hear from Gloria Iacoboni, MD...

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in chronic lymphocytic leukemia (CLL...

Therapeutic agents for patients with myelodysplastic syndromes (MDS) are currently under active investigation in clinical trials. The management of cytopenias, including anemia, is an important component in the treatment of lower-risk MDS (LR-MDS), and many agents are being evaluated to better manage these. In the context of higher-risk MDS (HR-MDS), many patients may fail to respond to novel agen...

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in chronic lymphocytic leukemia (CLL...

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in chronic lymphocytic leukemia (CLL...

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in chronic lymphocytic leukemia (CLL...

The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and researchers who discussed several topics. In this podcast series, you will hear the latest updates in the treatment of multiple myeloma and gain an insight into the sessions that took place at this year’s meeting. In this podcast, Gareth Morgan, MD, PhD, FRC...

Myeloproliferative neoplasms (MPNs) represent a heterogeneous group of diseases which remain a challenge to treat. While there have been several advances in the MPN treatment landscape, allogeneic stem cell transplantation (alloSCT) remains the only curative option for patients. There are several important factors to consider when selecting patients for transplant, and the introduction of novel ta...

The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and researchers who discussed several topics. In this podcast series, you will hear the latest updates in the treatment of multiple myeloma and gain an insight into the sessions that took place at this year’s meeting. In this podcast, Irene Ghobrial, MD, Dana-Fa...

The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and researchers who discussed several topics. In this podcast series, you will hear the latest updates in the treatment of multiple myeloma and gain an insight into the sessions that took place at this year's meeting.  In this podcast, Leif Bergsagel, MD, Mayo C...

Allogeneic stem cell transplantation (alloSCT) remains a valuable treatment option for fit patients with acute myeloid leukemia (AML), and the importance of measurable residual disease (MRD) monitoring in this malignancy is well established. Several clinicians and researchers are conducting trials to further evaluate how to improve outcomes for patients undergoing alloSCT. In this podcast, you wil...